Use

NavDx® is a clinically validated circulating tumor‑tissue‑modified HPV (TTMV®) DNA blood test that aids in the detection of HPV‑driven cancers — particularly HPV+ head and neck cancer, and is being expanded to anal squamous cell carcinoma. It quantifies fragments of TTMV‑HPV DNA shed by cancer cells into the blood, helping to detect active disease, assess treatment response, monitor molecular residual disease, and identify recurrences earlier than imaging modalities. The test has high predictive accuracy (≥95% PPV and NPV).